These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17627530)

  • 1. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
    Ferenczy MW
    Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.
    Stanfield BA; Kousoulas KG; Fernandez A; Gershburg E
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC;
    Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
    Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E
    Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of vaccine research and development of vaccines for herpes simplex virus.
    Johnston C; Gottlieb SL; Wald A
    Vaccine; 2016 Jun; 34(26):2948-2952. PubMed ID: 26973067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in herpes simplex virus vaccines: old problems and new challenges.
    Rajcáni J; Durmanová V
    Folia Microbiol (Praha); 2006; 51(2):67-85. PubMed ID: 16821715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunobiology of herpes simplex virus (HSV) infections.
    Corey L
    Herpes; 2001 Mar; 8 Suppl 1():1A. PubMed ID: 11867026
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine value profile for herpes simplex virus.
    Johnston C; Scheele S; Bachmann L; Boily MC; Chaiyakunapruk N; Deal C; Delany-Moretlwe S; Lee S; Looker K; Marshall C; Mello MB; Ndowa F; Gottlieb S
    Vaccine; 2024 Jul; 42(19S1):S82-S100. PubMed ID: 39003018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2.
    Mori I; Liu B; Goshima F; Ito H; Koide N; Yoshida T; Yokochi T; Kimura Y; Nishiyama Y
    Microbes Infect; 2005 Dec; 7(15):1492-500. PubMed ID: 16054416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.
    Chentoufi AA; Kritzer E; Yu DM; Nesburn AB; Benmohamed L
    Clin Dev Immunol; 2012; 2012():187585. PubMed ID: 22548113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex: insights on pathogenesis and possible vaccines.
    Koelle DM; Corey L
    Annu Rev Med; 2008; 59():381-95. PubMed ID: 18186706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of prophylactic vaccines for genital and neonatal herpes.
    Jones CA; Cunningham AL
    Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review.
    Bernstein DI
    Antiviral Res; 2020 Aug; 180():104821. PubMed ID: 32544409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.